Wave Life Sciences is trading at $6.34, up 5.34% in pre-market ahead of its planned Singapore-to-U.S. redomiciliation, expected after the August 7 close.

  • Shareholder and Singapore High Court approvals are complete, with SEC filings planned afterward.
  • Late-July earnings showed weaker revenue and a wider loss, making the corporate action the clearest current catalyst.
  • Broader markets are modestly higher, but not strongly enough to explain the move alone.